Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.
A 73-year-old woman presented with pruritic, itchy, and painful lesions on her hand, showing an appearance consisted of tripe palms. It was later revealed by doctors that her velvety palms turned out to be a rare sign of lung cancer.
The University of Barcelona and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic and antifibrotic drug, for the treatment of lung cancer.
Genetically targeted drugs and immunotherapies are transforming the way we treat many forms of lung cancer.
More than $2.3 million in Research Scholar Grants from the American Cancer Society have been awarded to three Rutgers Cancer Institute of New Jersey researchers to examine cell metabolism and tumor formation in forms of breast cancer, lung cancer and leukemia.
Many patients with early stage lung cancer who are age 90 years and older do not receive treatment; however, surgery in this nonagenarian population should be considered because it could significantly increase the chances for 5-year survival, according to research published online today in The Annals of Thoracic Surgery.
A new study found that cancer patients with a pre-existing autoimmune disease receiving immune checkpoint inhibitors as treatment are likely to experience a flare.
Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system.
The Human Immune Monitoring Center at the Icahn School of Medicine at Mount Sinai will apply cutting-edge high-throughput technologies to evaluate the therapeutic effects of Libtayo (cemiplimab-rwlc), a PD-1 antibody blockade developed by biotechnology company Regeneron Pharmaceuticals, Inc and Sanofi.
Only about 6 in 10 lung cancer patients in the United States receive the minimal lung cancer treatments recommended by the National Comprehensive Cancer Network guidelines, according to new research published online in the Annals of the American Thoracic Society.
The immune system must strike an exquisite balance between vanquishing infections and cancer, while at the same time restraining its activity to avoid inadvertently attacking the body's healthy tissues and organs.
Lung cancer is the second most common type of cancer and leading cause of cancer death in men and women, with non-small cell lung cancer (NSCLC) accounting for up to 90% of cases. Somatic mutations heavily impact the sensitivity of NSCLC patients to various drug treatments, and are critical for choosing the most effective targeted therapies for this cancer.
Immunotherapy is one of the latest and most effective armaments against various types of cancers. Some of the immunotherapy drugs such as PD-1 inhibitor Keytruda from Merck can block certain proteins in the cancer cells that can make the cells invisible to the immune system normally. Some of the cancers cells can now develop other ways to disguise themselves from being killed by the immune system.
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine have identified a new pathway that leads to the destruction of cancer cells.
As tumor cells multiply, they often spawn tens of thousands of genetic mutations. Figuring out which ones are the most promising to target with immunotherapy is like finding a few needles in a haystack.
A study presented at the ESMO Congress 2019 has revealed that a blood test may soon be able to pick up circulating tumor DNA to help avoid invasive tissue biopsies in lung cancer patients.
According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer, increasing progression-free survival.
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer.
Scientists have developed a method which is able to switch ‘tumor suppressor’ genes back on after they have been silenced by cancer cells.
In early July, the German Institute for Quality and Efficiency in Health Care conducted two early benefit assessments to investigate whether certain drug combinations with pembrolizumab have advantages in comparison with the respective appropriate comparator therapy for patients with metastatic squamous or non-squamous non-small cell lung cancer.